Zacks Research Raises Earnings Estimates for HealthEquity

HealthEquity, Inc. (NASDAQ:HQY) – Research analysts at Zacks Research raised their FY2026 earnings estimates for shares of HealthEquity in a research note issued to investors on Wednesday, December 24th. Zacks Research analyst Team now forecasts that the company will earn $3.31 per share for the year, up from their previous estimate of $3.20. The consensus estimate for HealthEquity’s current full-year earnings is $2.32 per share.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Wednesday, December 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. HealthEquity had a net margin of 14.86% and a return on equity of 12.94%. The firm had revenue of $322.16 million for the quarter, compared to the consensus estimate of $320.92 million. During the same period in the prior year, the firm posted $0.78 earnings per share. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2026 guidance at 3.870-3.950 EPS.

A number of other equities research analysts have also recently commented on HQY. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $120.00 target price on shares of HealthEquity in a research report on Friday, December 5th. Wall Street Zen downgraded shares of HealthEquity from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. KeyCorp decreased their target price on shares of HealthEquity from $125.00 to $120.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 8th. BMO Capital Markets restated a “market perform” rating on shares of HealthEquity in a report on Thursday, December 4th. Finally, Barclays assumed coverage on HealthEquity in a research report on Monday, December 8th. They issued an “overweight” rating and a $118.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, HealthEquity has a consensus rating of “Moderate Buy” and an average price target of $120.27.

HealthEquity Stock Up 1.1%

HQY opened at $93.48 on Monday. The company has a market cap of $7.99 billion, a PE ratio of 42.88, a price-to-earnings-growth ratio of 1.35 and a beta of 0.18. HealthEquity has a twelve month low of $74.07 and a twelve month high of $116.65. The company has a 50-day moving average price of $97.28 and a 200 day moving average price of $95.74. The company has a quick ratio of 4.13, a current ratio of 4.13 and a debt-to-equity ratio of 0.46.

Institutional Investors Weigh In On HealthEquity

A number of institutional investors and hedge funds have recently modified their holdings of HQY. Farther Finance Advisors LLC grew its position in shares of HealthEquity by 232.4% in the second quarter. Farther Finance Advisors LLC now owns 246 shares of the company’s stock valued at $26,000 after purchasing an additional 172 shares during the last quarter. WPG Advisers LLC purchased a new stake in shares of HealthEquity during the 1st quarter worth about $28,000. True Wealth Design LLC increased its position in shares of HealthEquity by 3,522.2% in the third quarter. True Wealth Design LLC now owns 326 shares of the company’s stock worth $31,000 after acquiring an additional 317 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of HealthEquity in the 2nd quarter valued at $33,000. Finally, Cullen Frost Bankers Inc. lifted its holdings in shares of HealthEquity by 172.3% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 354 shares of the company’s stock valued at $37,000 after acquiring an additional 224 shares in the last quarter. Institutional investors and hedge funds own 99.55% of the company’s stock.

Insider Transactions at HealthEquity

In other HealthEquity news, EVP Elimelech Rosner sold 10,959 shares of HealthEquity stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $95.45, for a total transaction of $1,046,036.55. Following the transaction, the executive vice president owned 45,742 shares of the company’s stock, valued at $4,366,073.90. The trade was a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Delano Ladd sold 1,500 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $94.72, for a total value of $142,080.00. Following the transaction, the executive vice president directly owned 73,979 shares in the company, valued at approximately $7,007,290.88. This represents a 1.99% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 17,240 shares of company stock valued at $1,640,164. 1.50% of the stock is currently owned by corporate insiders.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.